Male hypogonadism was associated with a significantly higher prevalence of prolonged QTc interval compared to healthy age-matched controls (15.4% vs 0%, p<0.05).
Case-Control (n=52)
Does testosterone replacement therapy normalize prolonged QTc intervals in adult males with primary or secondary hypogonadism?
Male hypogonadism is associated with an increased prevalence of prolonged QTc interval, which appears to normalize with testosterone replacement therapy.
Tasa de eventos absoluta: 15.4% vs 0%
valor p: p=<0.05
Symptoms and signs of male hypogonadism span all organ systems, including the cardiovascular apparatus. The electrocardiographic QT interval reflects cardiac ventricular repolarization and, if prolonged, increases the risk of malignant arrhythmias. QT interval duration is similar in boys and girls during childhood, but shortens in males after puberty and experimental studies suggest that testosterone is a major contributor to shortening of QT interval in men. The aim of the present pilot study was to assess the duration of ventricular repolarization in adult males with primary or secondary hypogonadism. Standard ECG recordings were performed in 26 men (mean age 39.2 +/- 2.17 years) with pituitary or testicular hypogonadism and repeated in 15 patients during testosterone replacement. Twenty-six age-matched control men were also analysed. Measured QT intervals were corrected for heart rate according to Bazzett's formula (QTc = QT/radical RR interval). The prevalence of prolonged QTc was considerably higher in hypogonadal patients (four of 26 men) than in control men (none, p < 0.05) and in the general, healthy population (<2.5%). QTc interval normalized on hormone replacement therapy in the four patients presenting prolonged QTc in the hypogonadal state. Heart rate and left ventricular mass did not differ among the two groups and no known QT-prolonging factor was apparent in patients with abnormal QTc interval. In conclusion, a high number prolonged QT interval measurements was observed in hypogonadal men who may therefore be at increased risk for cardiac arrhythmias. This observation reveals an additional feature of male hypogonadism, which may benefit from testosterone replacement therapy.
Giraldi et al. (Fri,) conducted a case-control in Primary or secondary hypogonadism (n=52). Hypogonadism vs. Age-matched healthy control men was evaluated on Prolonged QTc interval (p=<0.05). Male hypogonadism was associated with a significantly higher prevalence of prolonged QTc interval compared to healthy age-matched controls (15.4% vs 0%, p<0.05).